Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site

Journal of Medicinal Chemistry

Volumn 40, Issue 6, 1997, Pages 841-850

  Di Fabio, Romano ^a   Capelli, Anna M ^a   Conti, Nadia ^a   Cugola, Alfredo ^a   Donati, Daniele ^a   Feriani, Aldo ^a   Gastaldi, Paola ^a   Gaviraghi, Giovanni ^a   Hewkin, Cheryl T ^a   Micheli, Fabrizio ^a   Missio, Andrea ^a   Mugnaini, Manolo ^a   Pecunioso, Angelo ^a   Quaglia, Anna M ^a   Ratti, Emiliangelo ^a   Rossi, Luciana ^a   Tedesco, Giovanna ^a   Trist, David G ^a   Reggiani, Angelo ^a  

^a GSK   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 INDOLECARBOXYLIC ACID; 3 [2 [(PHENYLAMINO)CARBONYL]ETHENYL] 4,6 DICHLOROINDOLE 2 CARBOXYLIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DIZOCILPINE; DRUG CARRIER; GAVESTINEL; GLYCINE RECEPTOR ANTAGONIST; KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; STRYCHNINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING AFFINITY; BRAIN MEMBRANE; CONTROLLED STUDY; CONVULSION; DRUG BINDING SITE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT;

EID: 0009482135     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960644a     Document Type: Article

References (66)

1. (a) Meldrum, B.; Garthwaite, J. Excitatory Amino Acid Neurotoxicity and Neurodegenerative Diseases. Trends Pharmocol. 1990, 11, 379-387.
2. (b) Choi, D. W. Cerebral Hypoxia: Some New Approaches and Unanswered Questions. J. Neurosci. 1990, 10, 2493-2501.
3. (c) Meldum, B. Protection Against Ischaemic Neuronal Damage by Drugs Acting on Excitatory Neurotransmission. Cerebrovasc. Brain Metab. Rev. 1990, 2, 27-57.
4. (d) McCullogh, J. Excitatory Anoino Acid Antagonists and their Potential for the Treatment of Ischemic Brain Damage in Man. Br. J. Clin. Pharmacol. 1992, 34, 106-114.
5. (a) Cotman, C. W.; Foster, A. C.; Lanthorn, T. H. Adv. Biochem. Biopharmacol. 1981, 27, 1-27.
6. (b) Watching, J. C.; Evans, R. H. Excitatory Ainino Acids Transmitters. Annu. Rev. Pharmacol. Toxicol. 1981, 21, 165-204.
7. Choi, D. W.; Rothman, S, M. The Role of Glutamate Neurotoxicity in Hypoxic-Ischemic Neuronal Death. Annu. Rev. Pharmacol. Toxicol. 1991, 31, 171-182.
8. (a) Wong, E. H. F.; Kemp, J. A. Site for Antagonism on the N-methyl-D-aspartate Receptor Channel Complex. Annu. Rev. Pharmacol. Toxicol. 1991, 31, 401-425.
9. (b) Meldrum, B., Eds. Excitatory Amino Acid Antagonists; Blackwall: Oxford, England, 1991.
10. Collingridge, G. L., Watkins, J. C., Eds. The NMDA Receptor, 2nd ed.; IRL Press: Oxford, England, 1994.
11. (a) Johnson, J. W.; Ascher, P. Glycine Potentiates the NMDA Receptor Response in Cultured Brain Mouse Neurones. Nature 1987, 325, 529-531.
12. (b) Kleckner, N. W.; Dingledine, R. Requirements for Glycine in Activation of NMDA Receptors Expressed in Xenopus Oocytes. Science 1988, 241, 835-837. Reviews:
13. (c) Thomson, A. M. Glycine is a Coagonist at the NMDA Receptor/Ion Channel Complex. Prog. Neurobiol. 1990, 35, 53-74.
14. (d) Huettner, J. E. Competitive Antagonism of Glycine at the N-Methyl-D-Aspartate (NMDA) Receptor. Biochem. Pharmacol. 1991, 41, 9-16.
15. (a) Morris, R. G. M.; Anderson, E.; Lynch, G. S.; Baudry, M. Selective Impairment of Learning and Blockage of Long-term Potentiation by an N-Methyl-D-Aspartate antagonist, AP5. Nature 1986, 319, 774-776.
16. (b) Koek, W.; Colpaert, F. C. Selective Blockade of N-Methyl-D-aspartate (NMDA)-induced Convulsions by NMDA Antagonists and Putative Glycine Antagonists: Relationship with Phenylcyclidine-like Behavioral Effects. J. Pharmacol. Exp. Ther. 1990, 252, 349-357.
17. (c) Chiamulera, C.; Costa, S.; Reggiani, A. Effect of NMDA and Strychnine-Insensitive Glycine Site Antagonists on NMDA-Mediated Convulsions and Learning. Psycopharmacology 1990, 112, 551-552.
18. Reviews: (a) Palfreyman, M. G.; Baron, M. B. Non-competitive NMDA Antagonists Acting at the Glycine Site. In Excitatory Amino Acid Antagonists; Meldrum, B., Ed.; Blackwell: Oxford, England, 1991; Chapter 6, pp 101-129. (b) Carter, A. J. Glycine Antagonists: Regulation of the NMDA Receptor-Complex by the Strychnine-Insensitive Glycine Site. Drugs Future 1992, 17 (7), 595-613. (c) Kemp, J. A.; Leeson, P. D. The Glycine Site of the NMDA Receptor - Five Years On. Trends Pharmacol. Sci. 1993, 14, 20-25. (d) Leeson, P. D.; Iversen, L. L. The Glycine Site on the NMDA receptor: Structure-Activity Relationships and Therapeutic Potential. J. Med. Chem. 1994, 37, 4053-4067. (e) Iversen, L. L.; Kemp, J. A. Non competitive NMDA Antagonists as Drug. In TAe NMDA Receptor, 2nd ed.; Collingridge, G. L., Watkins, J. C., Eds.; IRL Press: Oxford, England, 1994; Chapter 20, pp 469-486. (f) Di Fabio, R.; Gaviraghi, G.; Reggiani, A. Strychnine-Insensitive Glycine Binding Site and the NMDA Receptor. Chim. Ind. 1996, 78, 283-289.
19. Reviews: (a) Palfreyman, M. G.; Baron, M. B. Non-competitive NMDA Antagonists Acting at the Glycine Site. In Excitatory Amino Acid Antagonists; Meldrum, B., Ed.; Blackwell: Oxford, England, 1991; Chapter 6, pp 101-129. (b) Carter, A. J. Glycine Antagonists: Regulation of the NMDA Receptor-Complex by the Strychnine-Insensitive Glycine Site. Drugs Future 1992, 17 (7), 595-613. (c) Kemp, J. A.; Leeson, P. D. The Glycine Site of the NMDA Receptor - Five Years On. Trends Pharmacol. Sci. 1993, 14, 20-25. (d) Leeson, P. D.; Iversen, L. L. The Glycine Site on the NMDA receptor: Structure-Activity Relationships and Therapeutic Potential. J. Med. Chem. 1994, 37, 4053-4067. (e) Iversen, L. L.; Kemp, J. A. Non competitive NMDA Antagonists as Drug. In the NMDA Receptor, 2nd ed.; Collingridge, G. L., Watkins, J. C., Eds.; IRL Press: Oxford, England, 1994; Chapter 20, pp 469-486. (f) Di Fabio, R.; Gaviraghi, G.; Reggiani, A. Strychnine-Insensitive Glycine Binding Site and the NMDA Receptor. Chim. Ind. 1996, 78, 283-289.
20. Reviews: (a) Palfreyman, M. G.; Baron, M. B. Non-competitive NMDA Antagonists Acting at the Glycine Site. In Excitatory Amino Acid Antagonists; Meldrum, B., Ed.; Blackwell: Oxford, England, 1991; Chapter 6, pp 101-129. (b) Carter, A. J. Glycine Antagonists: Regulation of the NMDA Receptor-Complex by the Strychnine-Insensitive Glycine Site. Drugs Future 1992, 17 (7), 595-613. (c) Kemp, J. A.; Leeson, P. D. The Glycine Site of the NMDA Receptor - Five Years On. Trends Pharmacol. Sci. 1993, 14, 20-25. (d) Leeson, P. D.; Iversen, L. L. The Glycine Site on the NMDA receptor: Structure-Activity Relationships and Therapeutic Potential. J. Med. Chem. 1994, 37, 4053-4067. (e) Iversen, L. L.; Kemp, J. A. Non competitive NMDA Antagonists as Drug. In the NMDA Receptor, 2nd ed.; Collingridge, G. L., Watkins, J. C., Eds.; IRL Press: Oxford, England, 1994; Chapter 20, pp 469-486. (f) Di Fabio, R.; Gaviraghi, G.; Reggiani, A. Strychnine-Insensitive Glycine Binding Site and the NMDA Receptor. Chim. Ind. 1996, 78, 283-289.
21. Reviews: (a) Palfreyman, M. G.; Baron, M. B. Non-competitive NMDA Antagonists Acting at the Glycine Site. In Excitatory Amino Acid Antagonists; Meldrum, B., Ed.; Blackwell: Oxford, England, 1991; Chapter 6, pp 101-129. (b) Carter, A. J. Glycine Antagonists: Regulation of the NMDA Receptor-Complex by the Strychnine-Insensitive Glycine Site. Drugs Future 1992, 17 (7), 595-613. (c) Kemp, J. A.; Leeson, P. D. The Glycine Site of the NMDA Receptor - Five Years On. Trends Pharmacol. Sci. 1993, 14, 20-25. (d) Leeson, P. D.; Iversen, L. L. The Glycine Site on the NMDA receptor: Structure-Activity Relationships and Therapeutic Potential. J. Med. Chem. 1994, 37, 4053-4067. (e) Iversen, L. L.; Kemp, J. A. Non competitive NMDA Antagonists as Drug. In the NMDA Receptor, 2nd ed.; Collingridge, G. L., Watkins, J. C., Eds.; IRL Press: Oxford, England, 1994; Chapter 20, pp 469-486. (f) Di Fabio, R.; Gaviraghi, G.; Reggiani, A. Strychnine-Insensitive Glycine Binding Site and the NMDA Receptor. Chim. Ind. 1996, 78, 283-289.
22. Reviews: (a) Palfreyman, M. G.; Baron, M. B. Non-competitive NMDA Antagonists Acting at the Glycine Site. In Excitatory Amino Acid Antagonists; Meldrum, B., Ed.; Blackwell: Oxford, England, 1991; Chapter 6, pp 101-129. (b) Carter, A. J. Glycine Antagonists: Regulation of the NMDA Receptor-Complex by the Strychnine-Insensitive Glycine Site. Drugs Future 1992, 17 (7), 595-613. (c) Kemp, J. A.; Leeson, P. D. The Glycine Site of the NMDA Receptor - Five Years On. Trends Pharmacol. Sci. 1993, 14, 20-25. (d) Leeson, P. D.; Iversen, L. L. The Glycine Site on the NMDA receptor: Structure-Activity Relationships and Therapeutic Potential. J. Med. Chem. 1994, 37, 4053-4067. (e) Iversen, L. L.; Kemp, J. A. Non competitive NMDA Antagonists as Drug. In The NMDA Receptor, 2nd ed.; Collingridge, G. L., Watkins, J. C., Eds.; IRL Press: Oxford, England, 1994; Chapter 20, pp 469-486. (f) Di Fabio, R.; Gaviraghi, G.; Reggiani, A. Strychnine-Insensitive Glycine Binding Site and the NMDA Receptor. Chim. Ind. 1996, 78, 283-289.
23. Reviews: (a) Palfreyman, M. G.; Baron, M. B. Non-competitive NMDA Antagonists Acting at the Glycine Site. In Excitatory Amino Acid Antagonists; Meldrum, B., Ed.; Blackwell: Oxford, England, 1991; Chapter 6, pp 101-129. (b) Carter, A. J. Glycine Antagonists: Regulation of the NMDA Receptor-Complex by the Strychnine-Insensitive Glycine Site. Drugs Future 1992, 17 (7), 595-613. (c) Kemp, J. A.; Leeson, P. D. The Glycine Site of the NMDA Receptor - Five Years On. Trends Pharmacol. Sci. 1993, 14, 20-25. (d) Leeson, P. D.; Iversen, L. L. The Glycine Site on the NMDA receptor: Structure-Activity Relationships and Therapeutic Potential. J. Med. Chem. 1994, 37, 4053-4067. (e) Iversen, L. L.; Kemp, J. A. Non competitive NMDA Antagonists as Drug. In The NMDA Receptor, 2nd ed.; Collingridge, G. L., Watkins, J. C., Eds.; IRL Press: Oxford, England, 1994; Chapter 20, pp 469-486. (f) Di Fabio, R.; Gaviraghi, G.; Reggiani, A. Strychnine-Insensitive Glycine Binding Site and the NMDA Receptor. Chim. Ind. 1996, 78, 283-289.
24. (9) Moore, K. W.; Leeson, P. D.; Carling, R. W.; Tricklebank, M. D.; Singh, L. Anticonvulsant Activity of Glycine-Site NMDA Antagonists. 1. 2-Carboxyl Prodrugs of 5,7-Dichlorokynurenic Acid. Bioorg. Med. Chem. Lett. 1993, 3(1), 61-64. Carling, R. W.; Leeson, P. D.; Moseley, A. M.; Smith, J. D.; Saywell, K.; Tricklebank, M. D.; Kemp, J. A.; Marshall, J. R.; Foster, A. C.; Grimwood, S. Anticonvulsant Activity of Glycine-Site NMDA Antagonists. 2. Trans 2-Carboxy-4-Substituted Tetrahydroquinolines. Bioorg. Med. Chem. Lett. 1993, 3 (1), 65-70.
25. Moore, K. W.; Leeson, P. D.; Carling, R. W.; Tricklebank, M. D.; Singh, L. Anticonvulsant Activity of Glycine-Site NMDA Antagonists. 1. 2-Carboxyl Prodrugs of 5,7-Dichlorokynurenic Acid. Bioorg. Med. Chem. Lett. 1993, 3(1), 61-64. Carling, R. W.; Leeson, P. D.; Moseley, A. M.; Smith, J. D.; Saywell, K.; Tricklebank, M. D.; Kemp, J. A.; Marshall, J. R.; Foster, A. C.; Grimwood, S. Anticonvulsant Activity of Glycine-Site NMDA Antagonists. 2. Trans 2-Carboxy-4-Substituted Tetrahydroquinolines. Bioorg. Med. Chem. Lett. 1993, 3 (1), 65-70.
26. (a) Huettner, J. E. Indole-2-Carboxylic Acid: A Competitive Antagonist of Potentiation By Glycine at the NMDA Receptor. Science 1989, 243, 1611-1613.
27. (b) Salituro, F. G.; Harrison, B. L.; Baron, B. M.; Nyce, P. L.; Stewart, K. T.; McDonald, I. A. Indole Derivatives: Antagonists of the Strychnine-Insensitive Glycine Receptor Associated with the N-Methyl-D-Aspartate Receptor Complex. J. Med. Chem. 1990, 33, 2944-2946.
28. (c) Gray, N. M.; Dappen, M. S.; Cheng, B. K.; Cordi, A. A.; Biesterfeldt, J. P.; Hood, W. F.; Monahan, J. B. Novel Indole-2-Carboxylates as Ligands for the Strychnine-Insensitive N-Methyl-D-Aspartate-Linked Glycine Receptor. J. Med. Chem. 1991, 34, 1283-1292.
29. (d) Salituro, F. G.; Tomlinson, R. C.; Baron, B. M.; Demeter, D. A.; Weintraub, H. J. R.; McDonald, I. A. Design, Synthesis and Molecular Modeling of 3-Acylamino-2-carboxyindole NMDA Receptor Glycine Site Antagonists. Bioorg. Med. Chem. Lett. 1991, 1 (9), 455-460.
30. (e) Salituro, F. G.; Harrison, B. L.; Baron, B. M.; Nyce, P. L.; Stewart, K. T.; Kenne, J. H.; White, H. S.; McDonald, I. A. 3-(2-Carboxylindol-3-yl)propionic Acid-Based Antagonists of the N-Methyl-D-aspartic Acid Receptor Associated Glycine Binding Site. J. Med. Chem. 1992, 35, 1791-1799.
31. (f) Rowley, M.; Leeson, P. D.; Grimwood, S.; Foster, A.; Saywell, K. 2-Carboxy Indolines and Indoles as Potential Glycine/NMDA Antagonists: Effect of Five-membered Ring Conformation of Affinity. Bioorg. Med. Chem. Lett. 1992, 2 (12), 1627-1630.
32. (g) Rao, T. S.; Gray, N. M.; Dappen, M. S.; Cler, J. A.; Mick, S. J.; Emmett, M. R.; Iyergan, S.; Monahan, J. B.; Cordi, A. A.; Wood, P. L. Indole-2-Carboxylates, Novel Antagonists of the N-Methyl-D-Aspartate (NMDA)-Associated Glycine Recognition Sites: in vivo Characterization. Neuropharmacology 1993, 32 (2), 139-147.
33. (h) Smith, E. C. R.; McQuaid, L. A.; Calligaro, D. O.; OåopMalley, P. J. Structure-Activity Relationship of a Series of Glycine Antagonists Related to 5,7-Dichlorokynurenic acid and 3-(2-Carboxy-6-Chloroindol-3-yl)Acetic Acid. Bioorg. Med. Chem. Lett. 1993, 3 (1), 81-84.
34. Larock, R. C. Comprehensive Organic Transformations 972-976; VCH Publishers, Inc.: New York, 1989.
35. Di Fabio, R.; Summa, V.; Rossi, T. Synthesis of Amides: An Efficient and Chemoselective Method for the Preparation of β-lactam Derivatives Related to HLE Inhibitors. Tetrahedron 1993, 49 (11), 2239-2306 and references therein.
36. Kishimoto, H.; Simon, J. R.; Aprison, M. H. Determination of the Equilibrium Dissociation Constants at a Number of Glycine Binding Sites in Several Areas of the Rat Central Nervous System, Using a Na-Indipendent System. J. Neurochem. 1981, 37, 1015-1024.
37. Munson, P.D.; Rodbard, D. LIGAND: A Versatile Computerized Approach for Characterization of Ligand-binding Data. Anal. Biochem. 1980, 107, 220-239.
38. Van Amsterdam, F. Th. M.; Giberti, A.; Mugnaini, M.; Ratti, E. 3-[(±)-2-Carboxypiperazin-4-yl]propyl-1-Phosphonic Acid Recognizes Two N-Methyl-D-Aspartate Binding Sites in Rat Cerebral Cortex Membranes. J. Neurochem. 1992, 59 (5), 1850-1855.
39. 3H]-α-Amino-3-Hydroxy-5-Methyl-Isoxazole-4-Propionic Acid (AMPA) to Rat Cortex Membranes Reveals Two Sites or Affinity States. J. Recept. Res. 1991, 11 (5), 727-741.
40. 3H]Kainate Binding Sites with Different Molecular Target Sizes in Rat Cortex. Neurosci. Lett. 1986, 65, 47-52.
41. Kloog, Y.; Haring, R.; Sokolovsky, M. Kinetic Characterization of the Phenylcyclidine-N-Methyl-D-Aspartate Receptor Interaction: Evidence for Steric Blockade of the Channel. Biochemistry 1988, 27, 843-848.
42. Ratti, E.; Tacconi, S.; Graziani, F.; Gaviraghi, G. Requirement of the Glycine for the Glutamate Activity at the NMDA Receptor Site. Eur. J. Pharmacol. 1990, 183, 1665.
43. Arunlakshana, O.; Schild, H. O. Some Quantitative Use of Drug Antagonists Br. J. Pharmacol. 1959, 14, 48-58.
44. (a) Leeson, P. D.; Baker, R.; Carling, R. W.; Curtis, N. R.; Moore, K. W.; Williams, B. J.; Foster, A. C.; Donald, A. D.; Kemp, J. A.; Marshall, G. R. Kynurenic Acid Derivatives: Structure-Activity Relationship for Excitatory Amino Acid Antagonism and Identification of Potent and Selective Antagonists at the Glycine Site on the N-Methyl-D-Aspartate Receptor. J. Med. Chem. 1991, 34, 1243-1252.
45. (b) Leeson, P. D.; Carling, R. W.; Moore, K. W.; Moseley, A. M.; Smith, J. D.; Stevenson, G.; Chan, T.; Baker, R.; Foster, A. C.; Grimwood, S.; Kemp, J. A.; Marshall, G. R.; Hoogsteen, K. 4-Amino-2-Carboxytetrahydroquinolines. Structure-Activity Relationship for Antagonism at the Glycine Site of the NMDA Receptor. J. Med. Chem. 1992, 35, 1954-1968.
46. Mayer, D.; Naylor, C. B.; Motoc, I.; Marshall, G. R. A Unique Geometry of the Active Site of the Angiotensin-Converting Enzyme Consist with Structure-Activity Studies. J. Comput-Aided Mol. Des. 1987, 1, 3-16.
47. (a) Sybyl 6.0, TRIPOS Inc., St. Louis, MO.
48. (b) In this case, distance maps were built up considering the NH of the indole nucleus, the Cl substituent present at position C-6, the lone pairs of the carboxylic group at position C-2 of the indole ring, and those present on the oxygen atom of carbonyl group belonging to the C-3 side chain. In addition, several parameters affecting the AAA results were tuned with a "trial and error" procedure in order to increase the accuracy of the model. Two solutions (tuples) were obtained using superconstrained distance maps with a grid size of 0.5 Å and 10 degrees as rotatable bond increment. Conformations satisfying the distance map constraints were minimized and superimposed according to the previously defined pharmacophore points.
49. 50 = 3.7 mg/kg) in our study in contrast to what published by Rowley et al. (ref 10f). This discrepancy could be due to the different model used (DBA/2 model in mice).
50. Hansch, C.; Leo, A. Substituent constants for Correlation Analysis in Chemistry and Biology; John Wiley & Sons: New York, 1979.
51. Williams, S. G.; Norrington, F. E. Determination of Positional Weighting Factors for the Swain and Lupton Substituent Constants F and R. J. Am. Chem. Soc. 1976, 98, 508-516.
52. Hammett, L. P. Physical Organic Chemistry; McGraw-Hill: New York, 1940 and 1970.
53. Draper, N. R.; Smith, H. Applied Regression Analysis; Wiley: New York, 1981.
54. RS/1 v 4.4.1, Bolt Beranek and Newman Inc., 1992.
55. TSAR v.2.2, Oxford Molecular Ltd., 1993.
56. Daylight v4.41, Daylight Chemical Information Systems, 1995.
57. 32b calculated according to ref 32c.
58. (b) Wold, S. Cross-Validatory Estimation of a Number of Components in Factor and Principal Components. Techometrics 1978, 20, 397-405.
59. (c) Wold, S. Validation of QSARs. Quant. Struct. Act. Relat. 1991, 10, 191-193.
60. The correlation matrix is the default choice for measuring the degree of association if the parameters in the MRA module of RS1, the program used for the statistical calculations. For this reason, we use it here instead of the parameters' covariance table.
61. Kubinyi, H. Quantitative Structure Activity Relationships. Non Linear Dependence of Biological Activity on Hydrophobic Character: a New Model. Arzneim.-Forsch. 1976, 26, 1991-1997.
62. Tamura, A.; Graham, D. I.; McCullogh, J.; Teasdale, G. M. Focal Cerebral Ischemia in Rat: 1. Description of Technique and Early Neuropathological Consequences. J. Cereb. Blood. Flow Metab. 1981, 1, 53-60.
63. 50 = 0.76 mg/kg). Postischaemia, the administration of 3 mg/kg iv dose, 1, 3, and 6 h after the MCA occlusion resulted in a significant neuroprotective effect giving 83%, 65%, and 53% reduction of the infarct volume, respectively, (a) Reggiani, A.; Costa, S.; Pietra, C.; Ratti, E.; Trist, D.; Ziviani, L.; Gaviraghi, G. Neuroprotective Activity of GV150526A a Novel, Potent and Selective Glycine Antagonist. Eur. J. Neurol. 1995, 2 (2), 6. (b) Neuroprotection of GV150526A. Comparison with Reference Compounds. Pietra, C.; Ziviani, L.; Valerio, E.; Tarter, G.; Reggiani, A. Stroke 1996, 27 (1), 26. Di Fabio, R.; Cugola, A.; Donati, D.; Feriani, A.; Gaviraghi, G.; Ratti, E.; Reggiani, A.; Trist, D. Novel Substituted Indole-2-Carboxylates as Potent Glycine Antagonists. ACS Book of Abstracts, 211th ACS National Meeting, New Orleans, LA, 24-28 March 1996, Abstract 107. (c) Cugola, A.; Gaviraghi, G. Giacobbe, S. EP 568136, 3 Nov 1993.
64. 50 = 0.76 mg/kg). Postischaemia, the administration of 3 mg/kg iv dose, 1, 3, and 6 h after the MCA occlusion resulted in a significant neuroprotective effect giving 83%, 65%, and 53% reduction of the infarct volume, respectively, (a) Reggiani, A.; Costa, S.; Pietra, C.; Ratti, E.; Trist, D.; Ziviani, L.; Gaviraghi, G. Neuroprotective Activity of GV150526A a Novel, Potent and Selective Glycine Antagonist. Eur. J. Neurol. 1995, 2 (2), 6. (b) Neuroprotection of GV150526A. Comparison with Reference Compounds. Pietra, C.; Ziviani, L.; Valerio, E.; Tarter, G.; Reggiani, A. Stroke 1996, 27 (1), 26. Di Fabio, R.; Cugola, A.; Donati, D.; Feriani, A.; Gaviraghi, G.; Ratti, E.; Reggiani, A.; Trist, D. Novel Substituted Indole-2-Carboxylates as Potent Glycine Antagonists. ACS Book of Abstracts, 211th ACS National Meeting, New Orleans, LA, 24-28 March 1996, Abstract 107. (c) Cugola, A.; Gaviraghi, G. Giacobbe, S. EP 568136, 3 Nov 1993.
65. 50 = 0.76 mg/kg). Postischaemia, the administration of 3 mg/kg iv dose, 1, 3, and 6 h after the MCA occlusion resulted in a significant neuroprotective effect giving 83%, 65%, and 53% reduction of the infarct volume, respectively, (a) Reggiani, A.; Costa, S.; Pietra, C.; Ratti, E.; Trist, D.; Ziviani, L.; Gaviraghi, G. Neuroprotective Activity of GV150526A a Novel, Potent and Selective Glycine Antagonist. Eur. J. Neurol. 1995, 2 (2), 6. (b) Neuroprotection of GV150526A. Comparison with Reference Compounds. Pietra, C.; Ziviani, L.; Valerio, E.; Tarter, G.; Reggiani, A. Stroke 1996, 27 (1), 26. (c) Di Fabio, R.; Cugola, A.; Donati, D.; Feriani, A.; Gaviraghi, G.; Ratti, E.; Reggiani, A.; Trist, D. Novel Substituted Indole-2-Carboxylates as Potent Glycine Antagonists. ACS Book of Abstracts, 211th ACS National Meeting, New Orleans, LA, 24-28 March 1996, Abstract 107. (c) Cugola, A.; Gaviraghi, G. Giacobbe, S. EP 568136, 3 Nov 1993.
66. Still, C. W.; Kahan, M.; Mitra, A. Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43, 2923-2925.